Alexander Queck
Overview
Explore the profile of Alexander Queck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abedin N, Hein M, Queck A, Mucke M, Weiler N, Pathil A, et al.
Hepatol Commun
. 2024 Sep;
8(10).
PMID: 39330948
Background: Hospitalized patients with end-stage liver disease are at risk of malnutrition, reduced body function, and cognitive impairment due to HE. This combination may have an impact on in-hospital falls...
2.
Himmelsbach V, Jeschke M, Lange C, Scheiner B, Pinter M, Sinner F, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001504
Introduction: The tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib represent the first-line systemic therapy of choice for patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Under sorafenib and...
3.
Gu W, Schaaf L, Hortlik H, Zeleke Y, Brol M, Schnitzbauer A, et al.
Eur J Gastroenterol Hepatol
. 2023 Sep;
35(11):1289-1297.
PMID: 37724476
Background: To date, liver transplantation (LT) is the only curative treatment for cirrhosis and early-diagnosed progressive acute liver failure (ALF). However, LT results in morbidities and mortality even post-LT. Different...
4.
Gu W, Queck A, Trebicka J, Praktiknjo M
Hepatology
. 2023 Feb;
77(5):E101.
PMID: 36724869
No abstract available.
5.
Queck A, Praktiknjo M, Jansen C, Trebicka J
Hepatology
. 2022 Sep;
77(2):E37.
PMID: 36054411
No abstract available.
6.
Queck A, Schwierz L, Gu W, Ferstl P, Jansen C, Uschner F, et al.
Hepatology
. 2022 Jul;
77(2):466-475.
PMID: 35869810
Background: Ascites is a definitive sign of decompensated liver cirrhosis driven by portal hypertension. Although transjugular intrahepatic portosystemic shunt insertion (TIPS) is indicated for therapy of recurrent and refractory ascites,...
7.
Schulz M, Mengers J, Gu W, Drolz A, Ferstl P, Amoros A, et al.
Liver Int
. 2022 Jun;
43(1):180-193.
PMID: 35727853
Background & Aims: In ACLF patients, an adequate risk stratification is essential, especially for liver transplant allocation, since ACLF is associated with high short-term mortality. The CLIF-C ACLF score is...
8.
Queck A, Weiler N, Trebicka J
Clin Liver Dis (Hoboken)
. 2022 Jun;
19(5):191-193.
PMID: 35662867
Content available: Author Interview and Audio Recording.
9.
Ferstl P, Queck A, Bremer K, Filmann N, Weiler N, Welker M, et al.
Transpl Infect Dis
. 2022 May;
24(4):e13868.
PMID: 35598281
Objectives: Stenosis of the biliary anastomosis predisposes liver graft recipients to bacterial cholangitis. Antibiotic therapy (AT) is performed according to individual clinical judgment, but duration of AT remains unclear. Methods:...
10.
Gu W, Hortlik H, Erasmus H, Schaaf L, Zeleke Y, Uschner F, et al.
Lancet Reg Health Eur
. 2021 Dec;
12:100240.
PMID: 34901909
Background: Cirrhosis is known to have a high prevalence and mortality worldwide. However, in Europe, the epidemiology of cirrhosis is possibly undergoing demographic changes, and etiologies may have changed due...